When was Auron Therapeutics founded?

Auron Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Auron Therapeutics located?

Auron Therapeutics is headquartered in Wellesley, United States.

Who is the current CEO of Auron Therapeutics?

Kate Yen of Auron Therapeutics. They have also founded 1 company.

How many employees does Auron Therapeutics have?

As of Mar 01, 2026, the latest employee count at Auron Therapeutics is 10 - 49.

Is Auron Therapeutics a funded company?

Auron Therapeutics is a funded company, having raised a total of $118M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 16, 2020.

When was the latest funding round of Auron Therapeutics?

Auron Therapeutics' latest funding was a $***** Conventional Debt round on Aug 10, 2026, with participation from 0 investor.

Where does Auron Therapeutics rank among its competitors?

Auron Therapeutics ranks 19th amongst 447 active competitors, of which 169 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Evommune, which secured $125M in Feb, 2026.

Who are the top competitors of Auron Therapeutics?

Auron Therapeutics' top competitors include Septerna, Evommune and Philogen. Among them, Auron Therapeutics secured the most recent funding round in August, 2026.

Auron Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cancer therapeutics for the treatment of blood cancer. The company has developed its proprietary differentiation therapy used for the treatment of hematologic malignancies. It helps in reactivating endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a normal phenotype. It can be used to treat acute promyelocytic leukemia (APL) by differentiating malignant promyelocytes into non-cancerous cell neutrophils.

Website: www.aurontx.com/
Email ID: *****@aurontx.com

Key Metrics

Founded Year

2018

Location

Wellesley, United States

Stage

Series B

Total Funding

$118M in 5 rounds

Latest Funding Round

Conventional Debt, Aug 10, 2026, $*****

Investors

Polaris Partners & 13 more

Ranked

19^th among 447 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Septerna & 513 more

View Auron Therapeutics' full profile

Auron Therapeutics has raised a total funding of $118M over 5 rounds. Its first funding round was on Dec 16, 2020. Auron Therapeutics has 13 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Auron Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 10, 2026	5001977	Conventional Debt	3763717	1135010	9968488	8625589
Feb 04, 2025	2666047	Series B	5026702	2893670	6869765	Apollo Health Ventures & 7 more
Dec 18, 2024	2732666	Series B	8556560	2133061	8041674	5396235

Access funding benchmarks and valuations. Sign up today!

View details of Auron Therapeutics's funding rounds and investors

The founders of Auron Therapeutics are Matt Vander Heiden, Eytan Stein, Kate Yen and Ross Levine. Kate Yen is the CEO of Auron Therapeutics.

Here are the details of Auron Therapeutics' key team members:

Matt Vander Heiden: Co-Founder of Auron Therapeutics.
Eytan Stein: Co-Founder of Auron Therapeutics.
Kate Yen: Co-Founder & CEO of Auron Therapeutics.
Ross Levine: Co-Founder of Auron Therapeutics.

View details of Auron Therapeutics's Founder profiles and Board Members

Auron Therapeutics' employee count trend

Auron Therapeutics has 10 - 49 employees as of Mar 26. Here is Auron Therapeutics's employee count trend over the years:

Employee count trend for Auron Therapeutics

Uncover Auron Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Auron Therapeutics include Septerna, Evommune and Philogen. Here is the list of Top 10 competitors of Auron Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	71/100
2nd	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	69/100
3rd	Philogen 1996, Sovicille (Italy), Public	Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders	$69.7M	The Equity Club, Novacapital & 3 others	68/100
4th	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Orbimed & 11 others	66/100
5th	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	General Catalyst, Orbimed & 29 others	66/100
6th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
7th	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Bpifrance, Symbiosis & 11 others	65/100
8th	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	General Catalyst, CPMG & 12 others	65/100
9th	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	65/100
10th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, SR One & 11 others	64/100
19th	Auron Therapeutics 2018, Wellesley (United States), Series B	Developer of cancer therapeutics for the treatment of blood cancer	$118M	Mubadala, Qiming & 12 others	48/100